PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00404-014-3377-3.pdf
Reference97 articles.
1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29
2. Ozols RF (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33(2 Suppl 6):S3–S11
3. Waldmann A, Eisemann N, Katalinic A (2013) Epidemiology of malignant cervical, corpus uteri and ovarian tumours—current data and epidemiological trends. Geburtsh Frauenheilk 73(2):123–129
4. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the gynecologic cancer intergroup. J Clin Oncol 27(9):1419–1425
5. Bartholomeusz C, Gonzalez-Angulo AM (2012) Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):121–130
Cited by 169 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds;Experimental and Molecular Pathology;2024-08
2. Aberrant angiogenic signaling pathways: Accomplices in ovarian cancer progression and treatment;Cellular Signalling;2024-08
3. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target;International Journal of Biological Macromolecules;2024-06
4. Thiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking;Future Medicinal Chemistry;2024-05-15
5. Pharmacological efficacy and potential of the use of nitazoxanide, a thiazolide drug with a wide spectrum of action;Reviews on Clinical Pharmacology and Drug Therapy;2024-04-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3